Literature DB >> 32970306

Comparing an adiposopathy approach with four popular classifications schemes to categorize the metabolic profile of postmenopausal women.

Pascale Mauriège1,2, Antony D Karelis3,4, Nadine Taleb4, Andrée-Anne Clément5,6, Denis R Joanisse5,6.   

Abstract

Numerous classifications are used to discern metabolically healthy obese (MHO) from metabolically abnormal obese (MAO) individuals. The goal of this study was to compare a single phenotype approach, adiposopathy (i.e., the plasma adiponectin/leptin ratio), with four commonly used classifications (International Diabetes Federation (IDF), Karelis, Lynch, Wildman), all based on obesity with other risk factors), for their ability to discern phenotypic differences between MAO and MHO postmenopausal women. Anthropometry, body composition, blood pressure, cardiorespiratory fitness (CRF), lipid-lipoprotein, hepatic, inflammatory, and adipokine profiles, as well as glucose-insulin homeostasis, were assessed in 79 obese sedentary postmenopausal women (60 ± 5 years; body mass index, BMI, 34.0 ± 3.7 kg/m2). Abdominal subcutaneous adipose tissue (SCAT) expression of selected genes involved in fatty acid metabolism and inflammation was used as markers of tissue state (n = 48). Beyond their intrinsic criteria, adiposopathy was almost as effective as the Karelis definition in discerning differences in MHO for adiposity (reduced body weight, BMI, waist circumference, and fat mass), lipid-lipoprotein (lower triacylglycerol and higher HDL-cholesterol levels, reduced atherogenic ratios) and adipokine (higher adiponectin and lower leptin levels) profiles, and glucose-insulin homeostasis (lower insulin resistance) as well as for some SCAT gene expression related to lipolysis and lipogenesis, but was the only one able to distinguish these subjects for greater CRF. The other classifications revealed fewer differences between MAO and MHO women. These data suggest that considering a marker of AT dysfunction such as adiposopathy either alone or in addition to other criteria could be potentially interesting in discerning the MHO phenotype.

Entities:  

Keywords:  Adiponectin; Adipose tissue; Cardiometabolic risk; Insulin sensitivity; Leptin; Menopause

Mesh:

Substances:

Year:  2020        PMID: 32970306     DOI: 10.1007/s13105-020-00766-w

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  38 in total

1.  Molecular and morphologic characterization of superficial- and deep-subcutaneous adipose tissue subdivisions in human obesity.

Authors:  Raffaella Cancello; Alessandra Zulian; Davide Gentilini; Sabrina Maestrini; Alberto Della Barba; Cecilia Invitti; Davide Corà; Michele Caselle; Antonio Liuzzi; Anna Maria Di Blasio
Journal:  Obesity (Silver Spring)       Date:  2013-06-11       Impact factor: 5.002

Review 2.  Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation.

Authors:  K G M M Alberti; P Zimmet; J Shaw
Journal:  Diabet Med       Date:  2006-05       Impact factor: 4.359

3.  Percutaneous adipose tissue biopsy by mini-liposuction for metabolic studies.

Authors:  J P Bastard; J Cuevas; S Cohen; C Jardel; B Hainque
Journal:  JPEN J Parenter Enteral Nutr       Date:  1994 Sep-Oct       Impact factor: 4.016

Review 4.  Molecular insights into the role of white adipose tissue in metabolically unhealthy normal weight and metabolically healthy obese individuals.

Authors:  Flavia Badoud; Maude Perreault; Michael A Zulyniak; David M Mutch
Journal:  FASEB J       Date:  2014-11-19       Impact factor: 5.191

Review 5.  Overview of epidemiology and contribution of obesity to cardiovascular disease.

Authors:  Marjorie Bastien; Paul Poirier; Isabelle Lemieux; Jean-Pierre Després
Journal:  Prog Cardiovasc Dis       Date:  2013-10-24       Impact factor: 8.194

6.  High adiponectin concentrations are associated with the metabolically healthy obese phenotype.

Authors:  Carlos A Aguilar-Salinas; Eduardo García García; Lorena Robles; Daniela Riaño; Doris Georgina Ruiz-Gomez; Ana Cristina García-Ulloa; Marco A Melgarejo; Margarita Zamora; Luz E Guillen-Pineda; Roopa Mehta; Samuel Canizales-Quinteros; Ma Teresa Tusie Luna; Francisco J Gómez-Pérez
Journal:  J Clin Endocrinol Metab       Date:  2008-08-05       Impact factor: 5.958

7.  Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association.

Authors:  Harold E Bays; Peter P Toth; Penny M Kris-Etherton; Nicola Abate; Louis J Aronne; W Virgil Brown; J Michael Gonzalez-Campoy; Steven R Jones; Rekha Kumar; Ralph La Forge; Varman T Samuel
Journal:  J Clin Lipidol       Date:  2013-05-31       Impact factor: 4.766

Review 8.  The distinction of metabolically 'healthy' from 'unhealthy' obese individuals.

Authors:  Matthias Blüher
Journal:  Curr Opin Lipidol       Date:  2010-02       Impact factor: 4.776

9.  The relationship between adiposopathy and glucose-insulin homeostasis is not affected by moderate-intensity aerobic training in healthy women with obesity.

Authors:  Andrée-Anne Clément; Eléonor Riesco; Sébastien Tessier; Michel Lacaille; Francine Pérusse; Mélanie Coté; Jean-Pierre Després; John Weisnagel; Jean Doré; Denis R Joanisse; Pascale Mauriège
Journal:  J Physiol Biochem       Date:  2018-04-26       Impact factor: 4.158

Review 10.  Is adiposopathy (sick fat) an endocrine disease?

Authors:  H E Bays; J M González-Campoy; R R Henry; D A Bergman; A E Kitabchi; A B Schorr; H W Rodbard
Journal:  Int J Clin Pract       Date:  2008-08-04       Impact factor: 2.503

View more
  2 in total

1.  Special Issue: 2019 Consortium for Trans-Pyrenean Investigations on Obesity and Diabetes.

Authors:  Fermin I Milagro; Christian Carpéné
Journal:  J Physiol Biochem       Date:  2021-01-22       Impact factor: 4.158

2.  Contribution of markers of adiposopathy and adipose cell size in predicting insulin resistance in women of varying age and adiposity.

Authors:  Eve-Julie Tremblay; André Tchernof; Mélissa Pelletier; Nicolas Chabot; Denis R Joanisse; Pascale Mauriège
Journal:  Adipocyte       Date:  2022-12       Impact factor: 3.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.